Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2015-004112-38
    Sponsor's Protocol Code Number:C25004
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Trial now transitioned
    Date on which this record was first entered in the EudraCT database:2016-11-16
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2015-004112-38
    A.3Full title of the trial
    An Open-Label Study of Brentuximab Vedotin+Adriamycin, Vinblastine, and Dacarbazine in Pediatric Patients With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
    Studio in aperto di brentuximab vedotin+adriamicina, vinblastina e dacarbazina nei pazienti pediatrici con nuova diagnosi di linfoma di Hodgkin in stadio avanzato
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Brentuximab vedotin+Adriamycin, vinblastine, and dacarbazine in pediatric patients with advanced stage newly diagnosed Hodgkin lymphoma
    Brentuximab vedotin+adriamicina, vinblastina e dacarbazina nei pazienti pediatrici con nuova diagnosi di linfoma di Hodgkin in stadio avanzato
    A.4.1Sponsor's protocol code numberC25004
    A.7Trial is part of a Paediatric Investigation Plan Yes
    A.8EMA Decision number of Paediatric Investigation PlanP/263/2014
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorMillennium Pharmaceuticals Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportMillenium Pharmaceuticals Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationMillennium Pharmaceuticals Inc.
    B.5.2Functional name of contact pointResponsible Medical Officer
    B.5.3 Address:
    B.5.3.1Street Address40 Landsdowne Street
    B.5.3.2Town/ cityCambridge
    B.5.3.3Post codeMA 02139
    B.5.3.4CountryUnited States
    B.5.4Telephone number18446628532
    B.5.6E-mailGlobalOncologyMedinfo@takeda.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name ADCETRIS®
    D.2.1.1.2Name of the Marketing Authorisation holderTakeda Pharma A/S
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/08/596
    D.3 Description of the IMP
    D.3.1Product nameADCETRIS®
    D.3.4Pharmaceutical form Powder for concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNBRENTUXIMAB VEDOTIN
    D.3.9.1CAS number 914088-09-8
    D.3.9.2Current sponsor codeSGN-35
    D.3.9.3Other descriptive nameBRENTUXIMAB VEDOTIN
    D.3.9.4EV Substance CodeSUB32397
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Hodgkin lymphoma (HL), a neoplasm of lymphoid tissue which is histopathologically defined by the presence of malignant Hodgkin Reed-Sternberg (HRS) cells in a background of inflammatory cells.
    The proposed pediatric study has been designed to evaluate brentuximab vedotin as a component of a multiagent frontline chemotherapy regimen in patients with advanced stage, newly diagnosed HL, here defined as Stage III and Stage IV and a ≥50 Lansky Play-Performance or Karnofsky Performance Status.
    Linfoma di Hodgkin (LH), neoplas tessuto linfatico definita dal punto di vista istopatologico dalla presenza cell di Hodgkin Reed-Sternberg (HRS) malign su sfondo di cell infiammat. Studio pediatr proposto è stato disegnato per valutare brentuximab vedotin come componente di un regime chemioterapico multiag di prima linea nei pt con LH nuova diagnosi stadio avanzato,qui definito come stadio III e stadio IV e un punteg ≥50 nella scala Play-Performance di Lansky o nel perform status di Karnofsky
    E.1.1.1Medical condition in easily understood language
    Hodgkin lymphoma (HL)
    Linfoma di Hodgkin (LH)
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 19.0
    E.1.2Level HLGT
    E.1.2Classification code 10025319
    E.1.2Term Lymphomas Hodgkin's disease
    E.1.2System Organ Class 10005329 - Blood and lymphatic system disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Phase 1 Primary Objective:
     To assess the safety and tolerability, and to identify the recommended dose of brentuximab vedotin when combined with multiagent chemotherapy regimen AVD for first-line treatment of advanced stage HL in pediatric patients.

    Phase 2 Primary Objectives:
     To evaluate the CR rate of pediatric patients with advanced stage HL at the end of protocol therapy.
     To determine the percentage of patients who are PET- after 2 cycles of protocol therapy.
     To evaluate the PR rate of pediatric patients with advanced stage HL at the end of protocol therapy.
     To evaluate the ORR of pediatric patients with advanced stage HL at the end of protocol therapy.
     To determine the percentage of patients who are able to complete 6 cycles of protocol therapy at the
    recommended dose.
    Obiettivo primario della fase 1:
    Valutare la sicurezza e la tollerabilità e identificare la dose raccomandata di brentuximab vedotin in combinazione con il regime chemioterapico multiagente AVD per il trattamento di prima linea del LH in stadio avanzato nei pazienti pediatrici.

    Obiettivi primari della fase 2:
    • Valutare il tasso CR dei pazienti pediatrici con LH in stadio avanzato alla fine della terapia del protocollo.
    • Determinare la percentuale di pazienti che risultano PET dopo 2 cicli di terapia del protocollo.
    • Valutare il tasso PR dei pazienti pediatrici con LH in stadio avanzato alla fine della terapia del protocollo.
    • Valutare l’ORR dei pazienti pediatrici con LH in stadio avanzato alla fine della terapia del protocollo.
    • Determinare la percentuale di pazienti in grado di completare 6 cicli di terapia del protocollo alla dose raccomandata.
    E.2.2Secondary objectives of the trial
    Phase 1 Secondary Objectives:
     To describe the maximum observed concentration (Cmax), area under the concentration-time curve from time 0 to 15 days (AUC0-15), and time of first time of occurrence of Cmax (Tmax) of brentuximab vedotin, monomethyl auristatin E (MMAE), and total (free and conjugated) therapeutic antibody (TAb).

    For further - please refer to Protocol

    Phase 2 Secondary Objectives:
     To evaluate the progression-free survival (PFS), event-free survival (EFS), overall survival (OS), and duration of response (DOR) in pediatric patients with advanced stage HL treated with protocol therapy.

    For further - please refer to Protocol
    Obiettivi primari della fase 1:
    • Descrivere la concentrazione massima osservata (Cmax), l’area sotto la curva concentrazione-tempo dal momento 0 a 15 giorni (AUC0-15) e il tempo al primo raggiungimento della Cmax (Tmax) di brentuximab vedotin, monometil auristatin E (MMAE) e anticorpi terapeutici (TAb) totali (liberi e coniugati).
    Per ulteriori dettagli si faccia riferimento al protocollo

    Obiettivi secondari della fase 2:
    • Valutare sopravvivenza la libera da progressione (PFS), la sopravvivenza libera da eventi (EFS), la sopravvivenza globale (OS) e la durata della risposta (DOR) nei pazienti pediatrici con LH in stadio avanzato trattati con la terapia del protocollo.
    Per ulteriori dettagli si faccia riferimento al protocollo
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Main Criteria for Inclusion:
    Male or female patients aged 5 to <18 years with newly diagnosed classical CD30+ advanced stage (Stage III and Stage IV) HL who are treatment naïve with Karnofsky Performance Status or Lansky Play-Performance ≥50.
    Pazienti di sesso maschile o femminile di età compresa tra 5 e <18 anni con nuova diagnosi di LH classico CD30+ in stadio avanzato (stadio III e stadio IV) naïve al trattamento con uno stato di validità secondo Karnofsky o un punteggio Lansky (valutazione della capacità di gioco) ≥50.
    E.4Principal exclusion criteria
    Main Criteria for Exclusion:
    Patients may not have nodular lymphocyte-predominant HL, known active cerebral meningeal disease, including signs or symptoms of progressive multifocal leukoencephalopathy (PML) or any history of PML, sensory or motor peripheral neuropathy, or known hypersensitivity to brentuximab vedotin or any component of AVD.
    I pazienti non possono presentare LH a predominanza linfocitaria nodulare, malattia cerebrale/meningea attiva nota, inclusi segni o sintomi di leucoencefalopatia multifocale progressiva (PML) o anamnesi di PML, neuropatia periferica sensitivo-motoria o nota ipersensibilità a brentuximab vedotin o a qualsiasi componente della AVD.
    E.5 End points
    E.5.1Primary end point(s)
    Phase 1 Primary Endpoints
     Determination of the recommended dose of brentuximab vedotin in combination with AVD in a pediatric population.
     Percentage of patients who experience AEs from the first dose of protocol therapy through 30 days after administration of the last dose of protocol therapy.
     Percentage of patients who experience serious AEs (SAEs) from the first dose of protocol therapy through 30 days after administration of the last dose of protocol therapy.

    Phase 2 Primary Endpoints
     Percentage of patients who achieve a CR per IRF assessment at EOT per IWG criteria.
     Percentage of patients whose disease is PET- after 2 cycles of protocol therapy per IRF assessment.
     Percentage of patients who achieve a PR per IRF assessment at EOT per IWG criteria.
     Percentage of patients who achieve an OR per IRF assessment at EOT per IWG criteria.
     Percentage of patients who are able to complete 6 cycles of protocol therapy at the recommended dose.
    Endpoint primari della fase 1:
    • Determinazione della dose raccomandata di brentuximab vedotin in combinazione con AVD in una popolazione pediatrica.
    • Percentuale di pazienti che manifesta eventi avversi (EA) dalla prima dose della terapia del protocollo fino a 30 giorni dopo la somministrazione dell’ultima dose della terapia del protocollo.
    • Percentuale di pazienti che manifesta eventi avversi seri (SAE) dalla prima dose della terapia del protocollo fino a 30 giorni dopo la somministrazione dell’ultima dose della terapia del protocollo.

    Endpoint primari della fase 2:
    • Percentuale di pazienti che raggiunge una CR in base alla valutazione dell’IRF all’EOT secondo i criteri dell’IWG.
    • Percentuale di pazienti la cui malattia risulta PET- dopo 2 cicli di terapia del protocollo in base alla valutazione dell’IRF.
    • Percentuale di pazienti che raggiunge una PR in base alla valutazione dell’IRF all’EOT secondo i criteri dell’IWG.
    • Percentuale di pazienti che raggiunge una OR in base alla valutazione dell’IRF all’EOT secondo i criteri dell’IWG.
    • Percentuale di pazienti in grado di completare 6 cicli di terapia del protocollo alla dose raccomandata.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Please see above
    Vedi sopra
    E.5.2Secondary end point(s)
    Phase 1 Secondary Endpoints
     Mean Cmax and mean AUC0-15 of brentuximab vedotin (serum), TAb (serum), and MMAE (plasma).
     Median Tmax of brentuximab vedotin (serum), TAb (serum), and MMAE (plasma).
     Percentage of patients who achieve a CR per independent review facility (IRF) assessment at End of Treatment (EOT) per International Working Group (IWG) criteria.
     Percentage of patients who achieve a PR per IRF assessment at EOT per IWG criteria.
     Percentage of patients who achieve an overall response (OR) per IRF assessment at EOT per IWG criteria.
     Percentage of patients whose disease is PET- after 2 cycles of protocol therapy per IRF assessment.
     Percentage of patients whose disease is PET+ after 6 cycles of protocol therapy per IRF assessment.
     Percentage of patients who are ATA positive, persistently positive, or transiently positive, ATA titer and neutralizing ATA (nATA) positive at baseline, predose Cycle 2 Day 1, Cycle 4 Day 1, Cycle 6 Day 1, or at termination if treatment is terminated before Cycle 6, and at EOT.
     Impact of ATA and nATA on the safety, efficacy, and PK endpoints.

    Phase 2 Secondary Endpoints
     PFS, EFS, OS, DOR.
     Percentage of patients receiving irradiation for HL following study treatment.
     Percentage of patients who experience AEs from the first dose of protocol therapy through 30 days after administration of the last dose of protocol therapy.
     Percentage of patients who experience SAEs from the first dose of protocol therapy through 30 days after administration of the last dose of protocol therapy.
     Percentage of patients who are ATA positive, persistently positive, or transiently positive, ATA titer and nATA positive at baseline, predose Cycle 2 Day 1, Cycle 4 Day 1, Cycle 6 Day 1, or at termination if treatment is terminated before Cycle 6, and at EOT.
     Impact of ATA and nATA on the safety, efficacy, and PK endpoints.
     Mean Cmax and mean AUC0-15 of brentuximab vedotin (serum), TAb (serum), and MMAE (plasma).
     Median Tmax of brentuximab vedotin (serum), TAb (serum), and MMAE (plasma).
     Percentage of patients who experience peripheral neuropathy, regardless of seriousness, from the first dose of protocol therapy through study closure.
     Time to onset and time to resolution for all peripheral neuropathy events.
     Immune reconstitution (peripheral blood CD34+ count; enumeration of the total lymphocyte count and lymphocyte subsets; total Ig and IgG, IgM, and IgA levels; and levels of the antibodies to tetanus, HiB, and polio serotypes) at baseline, EOT, and at 6, 12, and 18 months (±1 month) after last dose, until the start of subsequent anticancer therapy (with the exception of radiotherapy administered as part of first-line therapy).
    Endpoint secondari della fase 1:
    • Cmax media e AUC0-15 media di brentuximab vedotin (siero), TAb (siero) e MMAE (plasma).
    • Mediana del Tmax di brentuximab vedotin (siero), TAb (siero) e MMAE (plasma).
    • Percentuale di pazienti che raggiunge una CR in base alla valutazione dell’IRF all’EOT secondo i criteri dell’IWG.
    • Percentuale di pazienti che raggiunge una PR in base alla valutazione dell’IRF all’EOT secondo i criteri dell’IWG.
    • Percentuale di pazienti che raggiunge una risposta globale (OR) in base alla valutazione dell’IRF all’EOT secondo i criteri dell’IWG.
    • Percentuale di pazienti la cui malattia risulta PET- dopo 2 cicli di terapia del protocollo in base alla valutazione dell’IRF.
    • Percentuale di pazienti la cui malattia risulta PET+ dopo 6 cicli di terapia del protocollo in base alla valutazione dell’IRF.
    • Percentuale di pazienti ATA-positivi, con positività persistente o positività transitoria, titolo ATA e ATA neutralizzanti (nATA)-positivi al basale, prima della dose al Ciclo 2 Giorno 1, Ciclo 4 Giorno 1, Ciclo 6 Giorno 1 o al termine del trattamento, se questo viene interrotto prima del Ciclo 6, e all’EOT.
    • Impatto di ATA e nATA sugli endpoint primari di sicurezza, secondari di efficacia e PK.
    Endpoint secondari della fase 2:
    • PFS, EFS, OS, DOR.
    • Percentuale di pazienti sottoposti a irradiazione per il LH in seguito al trattamento dello studio.
    • Percentuale di pazienti che manifesta EA dalla prima dose della terapia del protocollo fino a 30 giorni dopo la somministrazione dell’ultima dose della terapia del protocollo.
    • Percentuale di pazienti che manifesta SAE dalla prima dose della terapia del protocollo fino a 30 giorni dopo la somministrazione dell’ultima dose della terapia del protocollo.
    • Percentuale di pazienti ATA-positivi, con positività persistente o positività transitoria, titolo ATA e nATA-positivi al basale, prima della dose al Ciclo 2 Giorno 1, Ciclo 4 Giorno 1, Ciclo 6 Giorno 1 o al termine del trattamento, se questo viene interrotto prima del Ciclo 6, e all’EOT.
    • Impatto di ATA e nATA sugli endpoint primari di sicurezza, secondari di efficacia e PK.
    • Cmax media e AUC0-15 media di brentuximab vedotin (siero), TAb (siero) e MMAE (plasma).
    • Mediana del Tmax di brentuximab vedotin (siero), TAb (siero) e MMAE (plasma).
    • Percentuale di pazienti che manifesta neuropatia periferica, a prescindere dalla gravità, dalla prima dose della terapia del protocollo fino alla chiusura dello studio.
    • Tempo all’insorgenza e tempo alla risoluzione di tutti gli eventi di neuropatia periferica.
    • Immunoricostituzione (conta CD34+ nel sangue periferico; enumerazione della conta linfocitaria totale e sottogruppi di linfociti; livelli di immunoglobuline [Ig] totali e di IgG, IgM e IgA; e livelli di anticorpi contro tetano, Haemophilus influenzae di tipo B [HiB] e sierotipi di poliovirus) al basale, all’EOT e 6, 12 e 18 mesi (±1 mese) dopo l’ultima dose, fino all’avvio della successiva terapia antitumorale (ad eccezione della radioterapia somministrata come parte della terapia di prima linea).
    E.5.2.1Timepoint(s) of evaluation of this end point
    Please see above
    Vedi sopra
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) Yes
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other Yes
    E.7.1.3.1Other trial type description
    To determine the recommended dose
    Determinare la dose raccomandata
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned3
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA15
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Bulgaria
    Canada
    Italy
    Spain
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The primary analyses for the clinical study report will be conducted a minimum of 8 weeks after the last patient enrolled receives the last dose of protocol therapy. The updated analyses on the efficacy endpoints will be conducted after all patients enrolled in the study have had the opportunity to be followed for 2 years from the time of enrollment, and will be included in an addendum to the clinical study report.
    Le analisi primarie per il resoconto dello studio clinico saranno condotte almeno 8 settimane dopo che l’ultimo paziente arruolato avrà ricevuto l’ultima dose della terapia del protocollo. Le analisi aggiornate sugli endpoint di efficacia saranno condotte dopo che tutti i pazienti arruolati nello studio avranno avuto la possibilità di essere seguiti per 2 anni dal momento dell’arruolamento, e saranno incluse in un addendum al resoconto dello studio clinico.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years4
    E.8.9.1In the Member State concerned months7
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years4
    E.8.9.2In all countries concerned by the trial months7
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 61
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) Yes
    F.1.1.5.1Number of subjects for this age range: 12
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 49
    F.1.2Adults (18-64 years) No
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state35
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 45
    F.4.2.2In the whole clinical trial 61
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2017-01-30
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2017-01-17
    P. End of Trial
    P.End of Trial StatusTrial now transitioned
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 16:36:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA